What to Expect at the 2023 Revolutionizing Atopic Dermatitis Conference

The Revolutionizing Atopic Dermatitis (RAD) Conference was founded by Jonathan Silverberg, MD, PhD, MPH, in 2019. As the founder and conference chair, Silverberg wanted to develop and implement medical education activities in a meeting format to increase the understanding of atopic dermatitis and promote the best treatment pearls. Dermatology professionals from across the US will meet in Washington, DC, from April 29-May 1, 2023, to discuss the latest updates in atopic dermatitis management and treatment.

The RAD conference prides itself on providing high-quality atopic dermatitis content to all health care providers, including dermatologists, allergists, immunologists, primary care physicians, nurse practitioners, registered nurses, advanced practice registered nurses, physician assistants, and other allied health professionals. Patients/patient groups involved in the care of patients with atopic dermatitis are also welcome.

After attending this year’s RAD conference, attendees should be able to:

1. Discuss improved understanding of pathophysiology, disease course, and currently available treatment options in therapeutic decision-making for atopic dermatitis and related comorbidities
2. Apply principles of long-term management to tailor and optimize therapy for patients
3. Identify best-practice in therapeutics for atopic dermatitis
4. Incorporate new and emerging therapeutics into the management of atopic dermatitis
5. Relate racial and healthcare disparities and identify strategies to reduce disparities in atopic dermatitis

The annual 3-day conference is full of informative presentations, late-breaking data, expert panel discussions, and networking opportunities. The editors of Dermatology Times® will be covering the conference live in person, reporting on numerous engaging sessions, as well as conducting exclusive interviews with experts in the field. Some of the upcoming content from RAD includes:

• Systemic treatments in infants with atopic dermatitis
• Racial disparities in atopic dermatitis
• Long-term 4-year safety data of upadacitinib
• New discoveries in the science of atopic dermatitis
• Updates in teledermatology 
• The use of oral JAK inhibitors and systemic treatments for atopic dermatitis
• Ruxolitinib cream 1.5% efficacy data for moderate-to-severe chronic hand dermatitis

See the full RAD agenda here.

Leading industry experts will discuss new data, treatments, and approaches in atopic dermatitis management. Attendees are encouraged to attend the much-anticipated “Battle of the 2 Titans: Challenging Patient Cases – Who is Eligible for Systemic Treatment in Atopic Dermatitis” between Andrew Blauvelt, MD, MBA, and Jonathan Silverberg, MD, PhD, MPH, on Sunday, April 30th at 8:00 am ET. Make sure to keep up to date with the latest in coverage from the conference and subscribe to Dermatology Times to receive daily email updates.